KAKEN PHARMACEUTICAL CO., LTD.
|KAKEN PHARMACEUTICAL CO., LTD. Patent applications|
|Patent application number||Title||Published|
|20130225492||Sustained-Release Pharmaceutical Composition - Provided is a pharmaceutical composition, including a drug and a collagen, in which the composition is satisfactory in handleability and has sustained-release property. The sustained-release pharmaceutical composition includes: a drug; a collagen; and at least one kind of sugar selected from monosaccharides, disaccharides, trisaccharides, and tetrasaccharides. The inventors of the present invention have found that the in vivo administration of a collagen solution containing a sugar results in the gelation of a collagen. Based on this finding, the inventors have found that a composition containing a drug, a collagen, and a sugar can control the release rate of the drug, and such composition can be used as a sustained-release pharmaceutical composition.||08-29-2013|
|20130177900||COMPOSITION FOR MAINTAINING FUNCTION OF PLATELETS - A composition for maintaining a function of platelets, the composition comprising, as an active ingredient, a compound represented by the following general formula (I) or a salt thereof, or a solvate thereof:||07-11-2013|
|20130150586||PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES - An object is to provide a process for producing the compound of formula 1 in higher yield by the ring-opening addition reaction of epoxytriazole with amine under mild conditions without using a large excess of 4-methylenepiperidine. The process for producing (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol or an acid addition salt thereof comprises reacting (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-2-[(1H-1,2,4-triazol-1-yl)methyl]oxirane with an acid addition salt of 4-methylenepiperidine in a reaction solvent in the presence of a hydroxide of an alkali metal or an alkaline earth metal selected from the group consisting of lithium, sodium, calcium, and strontium, or a hydrate thereof.||06-13-2013|
|20130131180||N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICAMENT CONTAINING SAME - A compound represented by the following general formula (I) which has ADAM17 inhibitory activity, or a salt thereof, or a solvate thereof:||05-23-2013|
|20130072530||NOVEL EP4 AGONIST - Provided is a compound represented by the formula (1):||03-21-2013|
|20110110987||AGENT FOR REGENERATING TYMPANIC MEMBRANE OR EXTERNAL AUDITORY CANAL - Provided is a tympanic membrane or ear canal regeneration agent comprising a combination of a gelatin sponge that carries basic fibroblast growth factor (bFGF) and a covering material. The covering material is used not only to fix the gelatin sponge to the affected portion, but also for the purpose of preventing drying and infections to provide a culturing environment that is favorable for regenerating tissue isolated from the outside. To promote tissue regeneration, the margin of the tympanic membrane or ear canal defect is preferably freshened in advance.||05-12-2011|
|20110098481||NOVEL EP4 AGONIST - Provided is a compound represented by the formula (1):||04-28-2011|
|20100190754||AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF - An azolylmethylidenehydrazine derivative represented by the formula (I)||07-29-2010|
|20100152443||PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT - The present invention provides a pyrazole derivative of the general formula (1),||06-17-2010|
|20090018345||PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES - Disclosed are pyrazole-1-carboxylate derivatives of the general formula (1),||01-15-2009|
Patent applications by KAKEN PHARMACEUTICAL CO., LTD.